Zhengqi Zhang
Senior Scientist, Merck
Zhengqi Zhang is listed as Senior Scientist, Merck. Zhengqi is scheduled to speak at BPI West 2027 on 18 March 2027.
Compiled from published conference agendas; not yet confirmed by Zhengqi. Is this you? Claim this profile.
About
Antibody-drug conjugates (ADCs) are monoclonal antibodies linked to potent small-molecule chemotherapy agents. They are designed to improve targeted cancer therapy by reducing systemic toxicity and enhancing efficacy. A critical step in cysteine-based ADC manufacturing is the conjugation reaction, which involves reducing interchain disulfide bonds. Optimizing this process is complex and time-intensive, requiring thorough evaluation of multiple parameters to achieve optimal reduction and conjugation efficiency. The drug-to-antibody ratio (DAR) is a key quality attribute influencing ADC pharmacokinetics and pharmacodynamics. Therefore, robust, real-time monitoring of DAR throughout manufacturing is essential to support process development and ensure consistent product quality. Traditional methods such as HIC-LC and RP-LC (with UV detection) face challenges including lengthy sample preparation, long analysis times, and limited peak identification capabilities, hindering real-time monitori